Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implicationsOlga Geling, Hans-Georg Eichler
Clinical Trials (London, England)|February 18, 2018
The evolution of clinical trials: Can we address the challenges of the future?Hans-Georg Eichler, Fergus Sweeney
Nature Reviews. Drug Discovery|December 16, 2014
The Innovative Medicines Initiative: an engine for regulatory scienceMichel Goldman, Nathalie Seigneuret, Hans-Georg Eichler
Nature Reviews. Drug Discovery|October 15, 2016
Precision medicine and the changing role of regulatory agenciesAlasdair Breckenridge, Hans-Georg Eichler, Jonathan P Jarow
Nature Reviews. Drug Discovery|July 2, 2015
Assessing the relative efficacy of new drugs: an emerging opportunityHans-Georg Eichler, Andrew Thomson, Irmgard Eichler, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 18, 2006
Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?Hans-Georg Eichler, Sheldon X Kong, Jean-Pierre Grégoire
Cytotherapy|June 21, 2025
Considerations driving the choice in clinical trial design of cell and gene therapy products: weighing convenience versus necessityKeith Abrams, Alessandro Aiuti, Hans-Georg Eichler, et al.
Frontiers in Pharmacology|February 13, 2023
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursementHans-Georg Eichler, Michael Kossmeier, Markus Zeitlinger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 3, 2016
Facilitating Antibacterial Drug Development in a Time of Great NeedEdward Cox, Marco Cavaleri, Hans-Georg Eichler, et al.
Nature Reviews. Drug Discovery|September 13, 2008
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemmaHans-Georg Eichler, Francesco Pignatti, Bruno Flamion, et al.
Pageof 6